Shaping the Future of Oncology for Patients l Exelixis

Innovating medicine brings hope

CANCER IS OUR CAUSE

U.S. FDA approves new indication

Our flagship medicine is now available for certain patients with previously treated advanced neuroendocrine tumors.
Read Our Press Release

Because every day counts

Our success as a business is intrinsically tied to our ability to do more for patients.
Explore our 2024 Annual Report

Our environmental, social and governance initiatives

Learn more about these themes and progress in our Corporate Values & Sustainability Report.
Read Our 2024 Report

Inspired by science

We are innovating at the forefront of cancer care. Our comprehensive approach is powered by a broad array of diverse biotherapeutics and small molecule programs for the treatment of cancer exploring multiple modalities and mechanisms of action.

Leveraging deep expertise in chemistry and biology, as well as strategic partnerships, we are advancing various biotherapeutics that have the potential to become anti-cancer therapies, such as bispecific antibodies, antibody-drug conjugates and other innovative treatments.

Clinical Trials & Pipeline

Powered by innovation and hope

At Exelixis, cancer is our cause. Over the course of the past three decades, we’ve evolved into a multi-platform cancer company dedicated to creating treatment regimens that challenge the status quo and bring us closer to a potential cure – all to give more patients hope for the future.

Our Story